Lab-grown tumors reveal immune cells capable of killing small cell lung cancer

by Walter and Eliza Hall Institute of Medical Research

edited by Lisa Lock, reviewed by Robert Egan

Lisa Lock

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

Researchers have uncovered a previously overlooked immune cell that can recognize and kill small cell lung cancer, the most aggressive form of the disease globally. Published in Cancer Cell, the WEHI study found patients with higher levels of these cells lived longer, uncovering a hidden immune defense that could be exploited to attack these hard-to-treat tumors.

Researchers also showed existing drugs could be repurposed to boost the cancer-killing activity of these immune cells, opening new opportunities to strengthen current treatments and help more patients benefit from these therapies.

Finding a way to boost treatment responses for lung cancer

Small cell lung cancer (SCLC) is one of the world's deadliest diseases, with a five-year survival rate of less than 7%. While immunotherapy has transformed outcomes for other cancers, only a rare subset of SCLC patients will experience long-term benefits from the treatment. One major reason is that these cancers are often invisible to the conventional immune cells that immunotherapy treatments rely on, making them difficult to detect and treat.

The new Cancer Cell study reveals a previously unrecognized immune pathway that can override these invisibility powers, unlocking a potential new therapeutic avenue for SCLC patients.

Kate Sutherland, senior author on the paper and WEHI laboratory head, said the findings could help solve one of the field's most pressing questions: how to boost the number of lung cancer patients who respond to immunotherapy.

"For decades, we've known that small cell lung cancer is exceptionally good at hiding from the immune system," Sutherland said. "We've found an immune cell that appears to be able to see through that disguise.

"Strikingly, patients whose tumors contained more of these specialized immune cells often had better treatment outcomes. This is the strongest evidence yet that gamma delta T cells are present in small cell lung cancers and appear capable of fighting the disease.

"It suggests these cells may offer an alternative immune attack route for tumors that are able to evade conventional cancer-fighting immune cells, opening up new possibilities for treating a cancer that has seen few advances over the past decades."

Using mini tumors to uncover a new lung cancer treatment strategy

To test whether gamma delta T cells could fight cancer, researchers created miniature tumors in the lab using samples donated by patients through the Victorian Cancer Biobank in collaboration with the Royal Melbourne Hospital. These "mini tumors" represent one of the most realistic laboratory models of SCLC developed to date.

When the team combined the mini tumors with gamma delta T cells taken from the patients' own blood, they found the immune cells were highly effective at recognizing and killing SCLC cells.

The researchers discovered they could amplify this immune response by using two existing drugs—tarlatamab (a cancer treatment approved for SCLC) and zoledronate (approved for osteoporosis and cancer-related bone disease).

The team found zoledronate increased the number of gamma delta T cells available and enhanced their ability to recognize SCLC tumors. Tarlatamab acted like a magnetic force that brought the immune cells into closer contact with the cancer.

Together, these drugs significantly enhanced the gamma delta T cells' ability to attack the cancer cells, suggesting a potential new way to strengthen anticancer immunity in SCLC.

Dr. Jin Ng, first author on the paper, said the findings also raise the possibility of using existing gamma delta T cells for adoptive transfer therapies—where large numbers of these immune cells are grown outside the body and infused back into patients.

"For patients with lower gamma delta T cell levels, therapies such as zoledronate may offer a way to boost their cancer-fighting immune cells and responsiveness to treatments," Ng said. "As therapies that expand and reinfuse gamma delta T cells already exist, our findings raise the exciting possibility of rapidly translating this discovery into new treatment strategies.

"This could open an entirely new avenue for personalized treatment approaches in small cell lung cancer and other solid cancers that are often missed by conventional immune cells."

Gathering clues from landmark immunotherapy clinical trials

The team focused on gamma delta T cells after analyzing data from two practice-changing clinical trials—IMpower133 and CASPIAN—which established immunotherapy as a standard treatment for SCLC.

Using advanced genomic and computational analyses led by WEHI's genomics and bioinformatics teams, researchers were able to link a strong gamma delta T cell signature to patients who experienced the greatest benefit from immunotherapy.

The team now hopes to clinically translate the findings into a new class of immunotherapy drugs for small cell lung cancer, in an ongoing collaboration with researchers at the Doherty Institute.

Publication details

Jin Ng et al., γδ T cells modulate anti-tumor immunity in small cell lung cancer, Cancer Cell (2026). DOI: 10.1016/j.ccell.2026.08.015

Journal information: Cancer Cell

Key medical concepts

Small Cell Lung CarcinomaZoledronic AcidTarlatamab

Clinical categories

OncologyAllergy and immunologyPulmonary medicine Provided by Walter and Eliza Hall Institute of Medical Research Who's behind this story?

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Lab-grown tumors reveal immune cells capable of killing small cell lung cancer (2026, October 15) retrieved 16 October 2026 from https://medicalxpress.com/news/2026-10-lab-grown-tumors-reveal-immune.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.